TABLE 2.
CTX-M-15 variant | MIC (μg/ml)a |
||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
CAZ | CAZ-AVI | AMX | AMC | CF | FOX | CTX | ATM | FEP | ETP | IPM | |
Noneb | 0.25 | 0.25 | 2 | 2 | 16 | 4 | 0.06 | 0.25 | 0.023 | 0.003 | 0.25 |
M-15 | 16 | 0.5 | >256 | 4 | >256 | 8 | >32 | 16 | 1.5 | 0.006 | 0.38 |
M-15 R164G | 4 | 0.5 | >256 | 6 | 256 | 8 | 1 | 0.75 | 0.25 | 0.003 | 0.19 |
M-15 P167L | 4 | 0.5 | >256 | 4 | >256 | 8 | 0.38 | 0.75 | 0.19 | 0.012 | 0.25 |
M-15 P174Q | 4 | 0.5 | >256 | 4 | 256 | 12 | 0.75 | 0.75 | 0.75 | 0.008 | 0.25 |
M-15 P167Q | 8 | 0.5 | >256 | 4 | >256 | 8 | 0.75 | 0.75 | 0.25 | 0.008 | 0.38 |
M-15 P167A | 8 | 0.5 | >256 | 4 | >256 | 12 | 2 | 1.5 | 0.38 | 0.012 | 0.25 |
M-15 P167T | 16 | 0.5 | >256 | 6 | >256 | 8 | 1 | 2 | 0.38 | 0.008 | 0.25 |
M-15 T171S | 16 | 0.5 | >256 | 4 | >256 | 8 | >32 | 12 | 2 | 0.006 | 0.38 |
M-15 P167S | 64 | 2 | >256 | 6 | >256 | 12 | 8 | 3 | 2 | 0.032 | 0.25 |
M-15 L169Q | 256 | 0.5 | 16 | 4 | 32 | 8 | 32 | 6 | 3 | 0.023 | 0.25 |
M-15 L169Q G240D | 64 | 1 | 32 | 4 | 64 | 8 | 6 | >32 | 4 | 0.032 | 0.19 |
M-15 L169Q S130G | 32 | 16 | 24 | 12 | 32 | 8 | 0.25 | 0.25 | 0.75 | 0.004 | 0.25 |
M-15 L169Q S130G G240D | 8 | 4 | 32 | 24 | 8 | 8 | 0.38 | 0.38 | 0.38 | 0.004 | 0.19 |
M-15 S130G | 1 | 0.5 | >256 | 24 | 32 | 3 | 0.023 | 0.047 | 0.016 | 0.003 | 0.094 |
CAZ, ceftazidime; AVI, avibactam (4 μg/ml); AMX, amoxicillin; AMC, amoxicillin combined with clavulanate (2 μg/ml); CF, cephalothin; FOX, cefoxitin; CTX, cefotaxime; ATM, aztreonam; FEP, cefepime; ETP, ertapenem; IPM, imipenem.
None, plasmid control without blaCTX-M-15.